US 12,466,790 B1
Bis urea-based organoselenium compound and method for treating cancer
Tarek Ahmed Yousef, Riyadh (SA); Saad Shaaban, Almansourah (EG); Ahmed A. Al-Karmalawy, Baghdad (IQ); Marwa Sharaky, Cairo (EG); Hussein Ba-Ghazal, Riyadh (SA); and Mohamed Alaasar, Halle Saale (DE)
Assigned to IMAM MOHAMMAD IBN SAUD ISLAMIC UNIVERSITY, Riyadh (SA)
Filed by IMAM MOHAMMAD IBN SAUD ISLAMIC UNIVERSITY, Riyadh (SA)
Filed on Nov. 22, 2024, as Appl. No. 18/957,414.
Int. Cl. A61P 35/00 (2006.01); A61K 31/17 (2006.01); C07C 391/02 (2006.01)
CPC C07C 391/02 (2013.01) [A61K 31/17 (2013.01); A61P 35/00 (2018.01)] 16 Claims
 
1. A method for inhibiting in vitro growth of a cancer cell of a cancer cell line selected from the group consisting of HN9, HuH7, FaDu, MCF7, HEPG2, A549, HCT116, and A375, comprising:
contacting the cancer cell with a bis-(organoselanyl urea)aryl agent of formula (I):

OG Complex Work Unit Chemistry
wherein R1 is methyl, ethyl, n-propyl, isopropyl, n-butyl, isobutyl, sec-butyl, or t-butyl.